Hormonal
Postmenopausal estrogen therapy is associated with a reduced risk of coronary heart disease in prospective observational studies.
If you are postmenopausal, this study suggests that estrogen therapy might lower your risk of heart disease. However, this is an observational study, so other factors might be involved. Consult your doctor to weigh the benefits against potential risks like breast cancer or blood clots, as individual health profiles vary significantly.
We found that estrogen therapy was associated with a reduced risk of coronary heart disease.
Why this rating
Prospective observational study; higher than cross-sectional but lower than RCTs due to potential confounding.
Source
A Prospective Study of Postmenopausal Estrogen Therapy and Coronary Heart Disease
Meir J. Stampfer et al. · New England Journal of Medicine · 1985
DOI 10.1056/nejm198510243131703
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →